(RTTNews) - Serina Therapeutics (SER) announced that the FDA has placed a clinical hold on the Investigational New Drug application for SER-252, Serina's lead development program for advanced Parkinsons disease. The FDA has requested additional information related to a commonly used excipient in the formulation.
Serina said it expects to receive the FDA's formal clinical-hold letter within 30 days and will provide an update once it has aligned with the FDA on next steps and timelines.
Shares of Serina Therapeutics are down 8% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
